Relivar (dronabinol buccal) / Sumitomo Pharma, Tetra Bio-Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   176 News 
  • ||||||||||  Relivar (dronabinol buccal) / Sumitomo Dainippon, dronabinol oral / Generic mfg.
    Dronabinol prescribing at one hospital in a state with legalized recreational cannabis () -  Feb 20, 2020 - Abstract #ASAM2020ASAM_229;    
    This analysis signals that inpatient prescribing of dronabinol at one institution in a state with high-potency, legalized cannabis occurs with some frequency and may be increasing. Furthermore, prescribing of dronabinol is highest on small surgical subspecialty services, suggesting that prescribing culture varies widely on the inpatient services.
  • ||||||||||  dronabinol oral / Generic mfg.
    A Case of a Posterior Fossa Atypical Teratoid Rhabdoid Tumor in an Adult Female () -  Feb 11, 2020 - Abstract #ISPRM2020ISPRM_326;    
    Given such limited cases reported in adults, overall prognosis and impact of resection and adjuvant therapy remains unclear.Conclusions : AT/RT is a rare, potentially devastating diagnosis which can produce an array of neurologic and functional deficits. These patients would benefit from early access to a multidisciplinary team including oncology, neurosurgery and rehabilitation medicine to assist with ongoing care.
  • ||||||||||  dronabinol oral / Generic mfg.
    Clinical, Journal:  Impact of Cannabinoids on Symptoms of Refractory Gastroparesis: A Single-center Experience. (Pubmed Central) -  Jan 30, 2020   
    Conclusions Cannabinoids dramatically improve the symptoms of gastroparesis. Furthermore, an improvement in abdominal pain with cannabinoids represents a breakthrough for gastroparesis-associated abdominal pain treatment, for which there are currently no validated therapies.
  • ||||||||||  dronabinol oral / Generic mfg.
    Clinical, Journal:  Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. (Pubmed Central) -  Jan 29, 2020   
    This study indicates that dronabinol did not enhance the analgesic effects of oxycodone and increased abuse- and impairment-related subjective effects. These data suggest that dronabinol may not be an effective or appropriate opioid adjuvant; it could potentially increase opioid dose requirements, while increasing psychoactive opioid effects.
  • ||||||||||  Relivar (dronabinol buccal) / Sumitomo Dainippon, dronabinol oral / Generic mfg.
    Journal:  Dronabinol use in France between 2004 and 2017. (Pubmed Central) -  Jan 15, 2020   
    Increased neural activation in PFC represents a potential biomarker for cannabis intoxication. This first investigation into dronabinol in France underlines the need to further investigate prescription practices and efficacy so as to define conditions of good use and the place of dronabinol in pain management.
  • ||||||||||  palonosetron intravenous / Generic mfg.
    Review, Journal:  Cannabis and cannabinoids. (Pubmed Central) -  Dec 22, 2019   
    However, several limitations of the study have to be taken into considerations such as the open uncontrolled design and the retrospective data analysis. No abstract available
  • ||||||||||  dronabinol oral / generics
    Clinical, Journal:  Taste disorders following cancer treatment: report of a case series. (Pubmed Central) -  Nov 24, 2019   
    Treatment trials with current interventions for dysgeusia appeared effective and should be considered in cancer survivors. Understanding taste and flavor function during and following cancer treatment is important in developing rational prospective preventive and interventional strategies.
  • ||||||||||  dronabinol oral / generics
    Clinical, Review, Journal:  Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans. (Pubmed Central) -  Nov 8, 2019   
    Experimental therapies in gastrointestinal motility and functional disorders are focused predominantly on pain relief mediated through cannabinoid 2 receptors or inhibition of DAGLα to normalize colonic transit. In summary, cannabinoid mechanisms and pharmacology are relevant to the current and future practice of clinical gastroenterology.
  • ||||||||||  Sativex (nabiximols) / GW Pharma, Relivar (dronabinol buccal) / Sumitomo Dainippon
    Journal:  Cannabinoids for Treatment of Dystonia in Huntington's Disease. (Pubmed Central) -  Oct 24, 2019   
    Improvement of motor symptoms, mainly dystonia, led to several relevant improvements from a global clinical perspective such as improvement of care, gait and fine motor skills and weight gain. Moreover, we observed changes in behavior with less irritability and apathy, as well as less hypersalivation in some cases.
  • ||||||||||  dronabinol oral / generics
    Review, Journal:  Cannabis for medical purposes : Impact of the law of 6 March 2017 on physicians (Pubmed Central) -  Oct 8, 2019   
    To this end, they must send data to the Federal Institute for Drugs and Medical Devices providing information about treatment with cannabis-based medicinal products. When prescribing medical cannabis products as defined in the Act of 6 March 2017 amending the law on narcotic drugs and other regulations, physicians assume a special responsibility that goes far beyond the responsibility for the use of authorized finished medicinal products.
  • ||||||||||  Relivar (dronabinol buccal) / Sumitomo Dainippon
    Journal:  High-dose dronabinol treatment vs. medicinal cannabis flowers (Pubmed Central) -  Oct 8, 2019   
    This article reports a case of pronounced, chronic lumboischialgia, which was not satisfactorily controlled by conventional analgesic treatment. The level of pain under high-dose dronabinol treatment with oral and inhalative administration as well as the way to reimburse the cost of medicinal cannabis flowers, the treatment success and criteria of the economic prescription procedure are presented.
  • ||||||||||  ondansetron / generics, fluoxetine / generics, dronabinol oral / generics
    Efficacy of pharmacotherapy for OSA in adults: a systematic review and network meta-analysis (TP-13) -  Aug 26, 2019 - Abstract #ERS2019ERS_4395;    
    There is currently insufficient evidence to recommend any pharmacotherapy for OSA and no phase-III trials are available. Future studies are advised to account for the underlying mechanisms of the intervention, as current evidence suggests that pharmacotherapy may not be a stand-alone therapy in OSA.
  • ||||||||||  dronabinol oral / generics
    Review, Journal:  Acute emergencies in oncology (Pubmed Central) -  Aug 3, 2019   
    In addition to stage-adapted pain therapy, supportive measures such as nutritional supplementation, the use of dronabinol in cases of loss of appetite, and antipruritic therapies are outlined. This article provides a succinct summary of the most frequently observed dermato-oncological emergencies with references to the respective detailed literature of associated medical societies and guidelines.
  • ||||||||||  dronabinol oral / generics
    Review, Journal:  Medical Use of Cannabinoids. (Pubmed Central) -  Aug 1, 2019   
    In addition, some cannabinoid-based medications have already been approved in various countries, including nabilone and dronabinol capsules for the treatment of nausea and vomiting associated with chemotherapy, dronabinol capsules for anorexia, an oral solution of dronabinol for both vomiting associated with chemotherapy and anorexia, a Δ-tetrahydrocannabinol/cannabidiol oromucosal spray for pain related to cancer and for spasticity and pain associated with multiple sclerosis, and an oral solution of cannabidiol for Dravet and Lennox-Gastaut syndromes. Here, we review the available efficacy, safety and tolerability data for cannabinoids in a range of medical conditions.
  • ||||||||||  dronabinol oral / generics
    Retrospective data, Review, Journal:  Systematic review and meta-analysis of cannabinoids in palliative medicine. (Pubmed Central) -  Jul 11, 2019   
    In another study comparing megestrol to dronabinol in HIV patients, megestrol treatment led to higher weight gain without any differences in tolerability and safety. We found no convincing, unbiased, high quality evidence suggesting that cannabinoids are of value for anorexia or cachexia in cancer or HIV patients.
  • ||||||||||  dronabinol / generics
    Journal:  Cannabinoids for the treatment of chronic refractory pruritus. (Pubmed Central) -  Jul 3, 2019   
    We found no convincing, unbiased, high quality evidence suggesting that cannabinoids are of value for anorexia or cachexia in cancer or HIV patients. No abstract available
  • ||||||||||  megestrol / Generic mfg., Relivar (dronabinol buccal) - Sumitomo Dainippon, Tetra Bio / Pharma, dronabinol oral / Generic mfg.
    Biomarker, Journal:  Cancer Cachexia: Beyond Weight Loss. (Pubmed Central) -  Oct 5, 2017   
    Consequently, oncologists have a role in ensuring that these resources are available to their patients. In addition, in light of the promising investigational agents, it remains imperative to refer patients with cachexia to clinical trials so that available options can be expanded to effectively treat this pervasive problem.